Three articles have appeared in press since June 2018 based on clinical trials undertaken in the U.K., that highlight the medium to long-term durability of Sonablate treatments in the control of prostate cancer when used in the partial gland ablation setting.1,2,3  Across the three articles and a total of more than 1,800 men, salvage free survival (no need for a whole gland or systemic treatment) was greater than 90% out as far as 60 months.  This excellent disease control was accompanied by a pad-free incontinence rate of greater than 98% and maintenance of erectile function in more than 80% of men. An additional article based on Canadian experience produced roughly similar results. 14

Dr. Mark Carol, CEO of SonaCare Medical writes,“While few will continue to question the benefit of partial gland ablation with HIFU over more conventional treatments such as surgery and radiation therapy when it comes to side effect profile, these studies, authored by leaders in the field, continue to put to rest the concern that partial gland HIFU ablation in general is not a durable procedure. Studies featuring Sonablate continue to produce the best disease control and side effect profiles of any prostate ablation technology. Internal reports indicate that these same excellent outcomes are being experienced among men treated in the U.S., with a number of short-term studies by U.S. clinicians being prepared for publication.  Each of these studies demonstrate definitively that it is possible to achieve whole-gland equivalent cancer control rates without the concomitant side effect profile of whole gland treatments. Now, otherwise healthy men with prostate cancer can leave the hospital post focal HIFU treatment with their cancer under control yet still healthy. They can even return back to work and activities of daily living the very next day instead of having to wait the weeks required with surgery. This represents a remarkable achievement and a treatment option that should be made available to all men with prostate cancer!”

Four time board certified urologist Dr. Michael Lazar of California HIFU says, “In 2007, I investigated and became an early user of a new technology for treatment of prostate cancer called high intensity focused ultrasound, or HIFU. This exciting non-invasive technology uses ultrasound energy to create heat. This heat is precisely aimed at the cancerous portions of the gland to kill the cancer while sparing the normal regions. It is painless, bloodless and causes much less erectile dysfunction and almost no incontinence at all. It’s done under anesthesia and the men wake up and can get on a plane that day to go home and can return to normal activities almost immediately. The cancer control results equal radical prostatectomy without the side effect profile.”

Since Sonablate® received FDA clearance on October 09, 2015, more than 1,800 patients have had a Sonablate HIFU prostate procedure across the 40+ locations in the U.S., including top-tier academic institutions in California, Indiana, Oklahoma, Maryland, New York, Arizona, and Texas. Over 70 U.S. physicians now offer HIFU prostate tissue ablation to their patients as a minimally invasive alternative to surgery or radiation.


1 Guillaumier S, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol (2018), https://doi.org/10.1016/j.eururo.2018.06.006

2 Stabile et al. “Medium -term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer”. BJU 12 Feb 2019

https://www.ncbi.nlm.nih.gov/pubmed/30753756/

3 Johnston MJ et al. Urology. 2019 Aug 23 (19)30730-7. Focal High-intensity Focused Ultrasound Partial Gland Ablation for the Treatment of Localised Prostate Cancer: A Report of Medium-term Outcomes From a Single-center in the United Kingdom.”

4 Bass et al. Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. 2019; 201:113-119   https://www.ncbi.nlm.nih.gov/pubmed/30577402


Portions of this article sourced from Sonacare Medical article dated 11/7/2019 titled Multiple Articles Highlight the Benefits of Partial Gland Prostate Ablation Using Sonablate.


Dr. Lazar is part of Northern California Medical Associates (NCMA) and operates California HIFU in Santa Rosa. He is the medical director of HIFU Prostate Services, LLC, a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU).Dr. Michael Lazar offers a HIFU Program in partnership with HIFU Prostate Services, LLC (HPS). HIFU Prostate Services, LLC (HPS) is a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). HIFU prostate treatments are performed at San Francisco Surgery Center (SFSC). SFSC offers patients a state-of-the-art facility that is convenient to hotels and the airport.

Call Dr. Lazar at (707) 546-5553 for more information and to learn if you qualify , or simply fill out and submit the online form here.